Friday 6 November 2026 Export TXG’s income statement to Excel — free account

10x Genomics

10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.

Revenue: +1.12%
EPS: +31.8%
Free cash flow: −4.61%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

58.35 0.29 +0.50%

Follow TXG

Alert me

Market cap: $7.6B
P/E: 0.0×
Fwd P/E: −95.9×
Dividend yield: —
F-score: 6/9
Altman Z: 3.99
Beneish M: −3.23
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

10x Genomics (TXG) revenue by segment, product and region

Revenue by product or service $m

Line	FY2021	FY2020	FY2019	FY2018	FY2017
Single Cell	391 79.69%	—	—	—	—
Instruments	64 13.14%	40 13.43%	35 14.21%	37 24.97%	24 34.42%
Spatial	28 5.68%	—	—	—	—
Services	7 1.48%	6 2.02%	4 1.66%	2 1.47%	0 0.60%
Spatial	0 0.06%	—	—	—	—
Consumables	419	—	—	—	—
Revenue	490	299	246	146	71

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017
United States	347 53.90%	334 54.74%	360 58.20%	285 55.19%	258 52.66%	155 51.79%	133 54.20%	—	—
Europe, Middle East and Africa	162 25.16%	160 26.16%	142 22.99%	117 22.67%	108 22.12%	73 24.52%	58 23.59%	36 24.48%	19 26.17%
China	70 10.93%	57 9.38%	51 8.24%	64 12.46%	78 15.88%	42 13.97%	30 12.17%	15 10.30%	3 4.46%
Asia-Pacific (excluding China)	52 8.10%	46 7.52%	52 8.45%	41 7.98%	39 7.97%	—	—	—	—
Americas (excluding United States)	12 1.91%	13 2.20%	13 2.12%	9 1.70%	7 1.37%	—	—	—	—
North America, Excluding United States	—	—	—	—	—	5 1.53%	6 2.64%	—	—
North America	—	—	—	—	—	—	—	85 58.18%	44 61.37%
Americas	359	348	373	294	265	—	—	—	—
Asia-Pacific	122	103	103	106	117	—	—	—	—
Revenue	643	611	619	516	490	299	246	146	71

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Remaining performance obligations	Q4 FY2025	$34.4M	$33.2M	+3.61%

	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023	Q2 FY2023	Q1 FY2023	Q4 FY2022	Q3 FY2022	Q2 FY2022	Q1 FY2022	Q4 FY2021	Q3 FY2021	Q2 FY2021	Q1 FY2021	Q4 FY2020	Q3 FY2020	Q2 FY2020	Q1 FY2020	Q4 FY2019	Q3 FY2019
Remaining performance obligations	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.